YgiV promoter mutations cause resistance to cystobactamids and reduced virulence factor expression in Escherichia coli.

ABSTRACT: Antimicrobial resistance is one of the major health threats of the modern world. Thus, new structural classes of antimicrobial compounds are needed in order to overcome existing resistance. Cystobactamids represent one such new compound class that inhibit the well-established target bacterial type II topoisomerases while exhibiting superior antibacterial and resistance-breaking properties. Understanding potential mechanisms of emerging resistances is crucial in the development of novel antibiotics as they directly impact the future therapeutic application and market success. Therefore, the frequency and molecular basis of cystobactamid resistance in Escherichia coli was analyzed. High-level resistant E. coli mutants were selected and found to harbor single nucleotide polymorphisms in the p

SUBMITTER: Risch T 

PROVIDER: S-EPMC11721078 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature